It was recently announced that innovative medical company Tempus has raised more than $70 million in funds. The funds came from two core investors in the series C round, New Enterprise Associates and Investors Revolution Growth. Overall, Tempus has raised more than $130 million in three separate rounds of funding. This has all been raised since the company started in just 2015, launching it from a small medical startup to a top game changer in the field of cancer diagnostics. According to a recent article in Forbes Magazine, this brings the total valuation of Tempus to about $700 million dollars.
Tempus was co-founded by Eric Lefkofsky, who is a serial entrepreneur that also founded Groupon. He currently serves as Tempus’s Chief Executive Officer. Tempus is a rapidly growing technology company that focuses on data driven cancer care. It is a complete informational system that is seeking to become the world’s largest data base of cancer information.
Lefkofsky founded Tempus after realizing that although there is a mass of data about cancer treatment and research methods there was no singular operating system that allowed doctors to access that data. Most of the information was contained in physicians notes that were filed away at individual hospitals rather than a central system. Tempus is seeking to change all that by centralizing the data and information.
Lefkofsky’s vision is to utilize the power of technology to complete this process. This is incredibly beneficial for the cancer patients who can benefit from this information being in the hands of their oncologists and the team. Cancer care becomes completely personal with access to this multitude of information. Research gained from one patient can be accessed by an oncologist on the other side of the country in real time. Additionally, Tempus is scaling its Business to Business partnership. In 2016 they have partnered with the Cleveland Clinic, the Mayo Clinic and Duke University. Tempus continues to grow and scale, with more and more partnerships in the works for 2017 and beyond.